Thaum Lub Ib Hlis 14, 2026, Zhejiang Daoer Biotechnology Co., Ltd. (tom qab no hu ua "Daoer Biotechnology"), ib lub koom haum ntawm East China Pharmaceutical Co., Ltd. (tom qab no hu ua "Lub Tuam Txhab"), tau txais ib daim ntawv ceeb toom los ntawm US Food and Drug Administration (hereinafter) raws li daim ntawv thov rau US DR10624 txhaj tshuaj xa los ntawm Daoer Biotechnology tau pom zoo los ntawm US FDA thiab tuaj yeem ua hauv Tebchaws Meskas. Qhov taw qhia yog Metabolic Dysfunction Associated Stem Liver Disease (MASLD).
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Cov ntsiav tshuaj
(3) Capsules
(4) Txau
(5) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Peb muabtirzepatide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej specifications thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/news/peptides-nqi- npe- ntawm-bloom-tech-85355837.html
DR10624 yog lub ntiaj teb thawj zaug (Thawj: hauv chav kawm) ntev - ua peb qhov tshwj xeeb agonist ntawm nws tus kheej tsim los ntawm Doer Biotech, tsom mus rau fibroblast kev loj hlob yam tseem ceeb 21 receptor (FGF21R), glucagon receptor (GCGR), thiab glucagon zoo li peptide -1 receptor (GLP1{12}). DR10624 yog ib qho chimeric peptide tsom GLP-1R / GCGR ntawm N-terminus, fused nrog tus engineered IgG1 Fc, thiab fused nrog recombinant FGF21 mutant ntawm C-terminus ntawm Fc.
Kev txhaj tshuaj DR10624 tau ua tiav Phase I txoj kev tshawb fawb txog kev mob hnyav hypertriglyceridemia (SHTG) thiab tau txais cov txiaj ntsig zoo saum toj kawg nkaus tom qab kis tau. Yav dhau los, cov txiaj ntsig ntawm New Zealand Phase b / kev tshawb fawb soj ntsuam ntawm DR10624 rau kev kho mob rog rog ua ke nrog hypertriglyceridemia, uas tau nthuav tawm ntawm EASL Congress 2025, pom tias txo qis hauv siab lipid qib txog li 89% thiab qhov txheeb ze txo qis hauv triglycerides ntau dua 70% piv rau cov hauv paus ntsiab lus.
Thaum lub Kaum Ib Hlis 2025, cov txiaj ntsig ntawm Phase I1 kev tshawb fawb soj ntsuam ntawm DR10624 rau kev kho mob hypertriglyceridemia hnyav ("DR10624-201 txoj kev tshawb fawb") tau tshaj tawm ntawm AHA Scientific Sessions 2025. Tom qab 12 lub voj voog ntawm kev kho mob, piv rau cov placebo, tag nrho cov koob tshuaj 624-201 cov pab pawg tseem ceeb ntawm DR10 rejuvenation. nruab nrab feem pua txo qis mus txog 74.5%; Lub caij no, piv rau cov pab pawg placebo, lub siab rog cov ntsiab lus ntawm txhua pawg DR10624 koob tshuaj tau txo qis, nrog rau qhov nruab nrab feem pua nce txog 67%.
Gan Li Pharmaceutical Ondibta tau pom zoo los ntawm European Union kom nkag mus rau European lag luam
Thaum Lub Ib Hlis 14, 2026, Ganli Pharmaceutical Co., Ltd. (tom qab no hu ua Ganli Pharmaceutical, Tshuag code: 603087. SH) thiab nws tag nrho-tus tswv European lub chaw muag khoom Gan&LeePharmaceuticals Europe GmbH (tom qab no xa mus rau Ganjan Europe) (Tebchaws Europe lub npe: Ondibta, Suav lub npe lag luam: Chang Xiulin), nws tus kheej tsim los ntawm Ganli Pharmaceutical, tsis ntev los no tau pom zoo los ntawm European Commission (EC) los kho ntshav qab zib rau cov neeg laus, cov hluas thiab cov menyuam hnub nyoog 2 xyoos thiab siab dua.
Qhov kev pom zoo no qhia txog kev nkag mus ntawm Ganli Pharmaceutical's Ganjing Insulin Txhaj rau hauv European lag luam, uas yuav raug tsim tawm thiab muag hauv European Union (EU), Iceland, Liechtenstein, thiab Norway.
Ganjing membrane insulin yog qhov ntev - ua cov tshuaj insulin yooj yim analog, uas tau txhaj tshuaj subcutaneously ib hnub ib zaug thiab muaj cov nyhuv hypoglycemic kav ntev li 24 teev. Nws muaj cov yam ntxwv ntawm lub sijhawm ua haujlwm ntev, ruaj khov thiab tsis muaj ntshav siab cov tshuaj concentration, thiab tswj cov piam thaj kom ruaj khov.
Txog tam sim no, Chang Xiulin los ntawm Ganli Pharmaceutical yog thawj zaug thiab tsuas yog hauv tsev tsim cov tshuaj insulin glargine hauv Suav teb kom ua tiav lub taub hau mus rau lub taub hau kev sim tshuaj nrog cov tshuaj siv thawj (Sanofi: Lantus) hauv Tebchaws Europe thiab Tebchaws Meskas.
Hauv ntau dua 1100 tus neeg mob ntshav qab zib (xws li kwv yees li 580 tus neeg mob ntshav qab zib hom 1 thiab 570 tus neeg mob ntshav qab zib hom 2), nws tau lees paub tag nrho tias Changxiu Lin "/0ndibta" yog qhov sib npaug ntawm cov tshuaj siv thawj zaug ntawm kev ua tau zoo thiab kev nyab xeeb.
Tib lub sijhawm Siv cov txheej txheem "glucose clamp", uas yog tus qauv kub rau kev tshuaj xyuas cov tshuaj insulin, Ganli Pharmaceutical kuj tau ua thiab ua tiav lub taub hau mus rau lub taub hau kev tshawb fawb ntawm Ganli Ganjing Insulin U300 thiab thawj kev tshawb fawb (Sanofi: Laiyushi), lees paub tias ob qho tib si sib npaug ntawm kev nyab xeeb thiab kev nyab xeeb.
muaj peev xwm siv tau
Tam sim no, kev tshawb fawb tab tom tshawb nrhiav kev siv Tirzepatide hauv kev kho NASH. Vim Tirzepatide lub peev xwm los tswj cov piam thaj thiab lipid metabolism, txo cov rog rog, thiab txhim kho insulin tsis kam, cov txheej txheem ntawm kev ua haujlwm no yuav muaj txiaj ntsig zoo rau kev kho NASH. NASH muaj feem cuam tshuam nrog cov kab mob metabolic xws li rog rog thiab ntshav qab zib. Thaum txhim kho cov ntsuas metabolic, Tirzepatide tuaj yeem pab txo qis daim siab steatosis thiab inflammatory cov tshuaj tiv thaiv, yog li ncua kev kawm ntawm NASH.
Tirzepatide tseem tab tom ua kev sim tshuaj hauv kev kho mob pw tsaug zog apnea syndrome. Kev rog rog yog qhov tseem ceeb ntawm kev pheej hmoo rau pw tsaug zog apnea syndrome. Tirzepatide, los ntawm nws cov txiaj ntsig poob phaus, tuaj yeem txo cov rog hauv caj dab, txhim kho txoj hlab cua sab saud, thiab txo cov tsos mob ntawm pw tsaug zog apnea. Nyob rau tib lub sijhawm, nws cov kev tswj hwm cov txiaj ntsig ntawm cov metabolism kuj tseem tuaj yeem pab txhim kho kev noj qab haus huv tag nrho ntawm cov neeg mob thiab txhim kho kev pw tsaug zog zoo.
Lub luag haujlwm muaj peev xwm hauv kev kho mob raum mob ntev
Muaj cov kev tshawb fawb qhia tias Tirzepatide yuav muaj qee yam kev kho mob rau cov kab mob raum ntev. Nws tuaj yeem txo cov ntshav siab, txo cov tshuaj tiv thaiv kab mob, txhim kho lub raum hemodynamics, thiab yog li tiv thaiv lub raum ua haujlwm. Hauv kev sim tsiaj, Tirzepatide tuaj yeem txo qhov kev pheej hmoo ntawm daim siab thiab lub raum teeb meem, muab qee lub hauv paus rau nws daim ntawv thov hauv kev kho mob raum mob.